Theranostics represents a novel approach in modern medicine, merging diagnostic and therapeutic methods into a unified framework tailored to individual patient needs. The current review explores the impact of personalized radiopharmaceuticals on the evolution of theranostics, particularly within oncology. The development of these specialized agents has revolutionized the way diseases are detected and treated, offering a more precise method that targets specific molecular features of tumors. By combining the ability to diagnose and treat with the same radiopharmaceutical, theranostics enables a more focused and efficient treatment pathway, minimizing adverse effects while enhancing therapeutic success. Personalized radiopharmaceuticals play a crucial role in this approach, offering the ability to monitor disease activity and therapeutic response in real time, thus providing critical insights for ongoing care. Integrating these advanced techniques into clinical practice is paving the way for more individualized cancer treatment, aligning with the broader goal of precision medicine. As this field advances, theranostics is expected to significantly improve patient outcomes and quality of life, marking a significant leap forward in personalized cancer care.
Sushant et al. (Tue,) studied this question.